Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Vote In favor of Your Favored Web based Dating Application - 2Which Breakfast Enraptures Your Taste Buds? Vote
- 3Timex Gives Its Classic Affordable Field Watch a Tactical, Milspec Makeover
- 4Authentic Urban areas: Rich Legacy and Lively Societies
- 5New York to require social media platforms to display mental health warnings
- Osteoporosis, the silent disease, can shorten your life − here’s how to prevent fractures and keep bones healthy
- Russia downs 16 drones heading for Moscow, mayor says
- IDF destroys Hezbollah rocket launcher used in large rocket salvo towards Haifa, Galilee
- Flights canceled at 40 U.S. airports: Follow live updates as FAA cuts to air traffic take effect amid government shutdown
- Instructions to Pick the Right Senior Protection Plan.
- Putin says Russian forces will seize capital of Zaporizhzhya
- 2024 Watch Gathering: The Best Watches of the Year
- Solid Living Tips: Experiences from a Wellness Fan
- Palestine weekly wrap: Protests sweep West Bank after death penalty law
